Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295685 | 0.87 | PKM (0.49) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL3970403 | 0.87 | PKM (0.49) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL16986998 | 0.87 | PKM (0.49) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL26103503 | 0.86 | SMN1; SMN2 (0.42) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL1958618 | 0.85 | PKM (0.48) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL4129353 | 0.85 | PKM (0.48) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL22188562 | 0.85 | PKM (0.46) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL15437243 | 0.85 | PKM (0.46) | PKM | |
| SCHEMBL15437724 | 0.84 | PKM (0.47) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 | |
| SCHEMBL21963889 | 0.84 | PKM (0.47) | PKMUSP2SMN1; SMN2EPHX2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854856-B1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-3165530-B1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QILU PHARMACEUTICAL CO LTD (CN) | 2018-12-05 | — | — | EP | disclosed |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| US-9370516-B2 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders | PFIZER INC. (US) | 2016-06-21 | — | — | US | disclosed |
| WO-2016000581-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | 南京明德新药研发股份有限公司 | 2016-01-07 | — | — | WO | disclosed |
| EP-2547679-B1 | 2,3 DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER INC. (US) | 2015-04-30 | — | — | US | disclosed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8609680-B2 | 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | PFIZER INC. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2547679-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | Pfizer Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011114271-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | ALK, ROS1, ARSA | PKM 1722/4885USP2 4592/4885SMN1; SMN2 3417/4885 |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | GIPR, GHSR, HCRTR2 | PKM 3930/4885USP2 2224/4885SMN1; SMN2 1427/4885 |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | GIPR, GLP1R, GHSR | PKM 4238/4885USP2 3484/4885SMN1; SMN2 1617/4885 |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | ALK, ROS1, ARSA | PKM 1722/4885USP2 4592/4885SMN1; SMN2 3417/4885 |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | GIPR, GLP1R, GHSR | PKM 4298/4885USP2 3488/4885SMN1; SMN2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.